- Conditions
- Normal-weight Obesity, Obesity
- Interventions
- Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)
- Other
- Lead sponsor
- Oklahoma State University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Stillwater, Oklahoma
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 23,750
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, umbilical cord blood transplantation, methylprednisolone
- Biological · Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Up to 120 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Brain Tumor, Malignant Neoplasm of Fourth Ventricle of Brain
- Interventions
- Ommaya Reservoir, Methotrexate, Leucovorin
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Physical Activity
- Other
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years to 74 Years · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Weight Loss
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona
- Conditions
- Dermatitis, Atopic
- Interventions
- Dupilumab, Matching placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more
- Conditions
- Sarcoma
- Interventions
- Doxorubicin Hydrochloride, Radiation Therapy (RT)
- Drug · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Focus: Healthy Adults Without Brain Injury
- Interventions
- Not listed
- Lead sponsor
- Lindell Weaver
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Colorado Springs, Colorado
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, gp209-2M antigen, incomplete Freund's adjuvant
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Vulvar Intraepithelial Neoplasia, Condylomata Acuminata
- Interventions
- CUSA (Cavitronic Ultrasonic Surgical Aspirator)
- Device
- Lead sponsor
- Integra LifeSciences Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 56 participants
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
- Interventions
- CB-10-01 (Transgenic Lymphocyte Immunization)
- Biological
- Lead sponsor
- Cosmo Bioscience
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 5
- States / cities
- Duarte, California • Los Angeles, California • San Diego, California + 2 more
- Conditions
- Lymphangioleiomyomatosis, Lymphangiomyomas, Pleural Effusions, Ascites
- Interventions
- Octreotide
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
- Interventions
- ATI-045, Placebo
- Drug
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 53
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 47 more
- Conditions
- Breast Cancer
- Interventions
- 18F-fluorofuranylnorprogesterone, Positron Emissions Tomography / Magnetic Resonance Imaging, Anastrozole, Blood Sampling, FDA-approved gadolinium-based intravenous contrast agent
- Drug · Device · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Glioma
- Interventions
- LY2157299, Radiation, Temozolomide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 6
- States / cities
- La Jolla, California • San Francisco, California • Tampa, Florida + 3 more
- Conditions
- Atopic Dermatitis
- Interventions
- Ruxolitinib phosphate cream
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 23
- States / cities
- Hoover, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 17 more
- Conditions
- Sturge-Weber Syndrome
- Interventions
- Not listed
- Lead sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Other
- Eligibility
- 1 Month and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2027
- U.S. locations
- 7
- States / cities
- Baltimore, Maryland • Detroit, Michigan • New York, New York + 4 more
- Conditions
- Melanoma (Skin)
- Interventions
- MART-1 antigen, gp100 antigen
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Cambridge, Massachusetts • Houston, Texas
- Conditions
- Postoperative Wound Infection, Traumatic Wound Infection, Closed Soft Tissue Abscess
- Interventions
- Not listed
- Lead sponsor
- Brentwood Biomedical Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Sylmar, California
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Povorcitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 61
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 51 more
- Conditions
- Pediatric Retinoblastoma, Retinoblastoma
- Interventions
- Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V), California Verbal Learning Test, Children's Version, Beery Developmental Test of Visual Motor Integration, 6th edition, Grooved Pegboard Test, Behavior Assessment System for Children/Parent Report
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Palmoplantar Keratoderma
- Interventions
- Tapinarof
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Tissue Plasminogen Activator, Intraventricular Brain Hemorrhage
- Interventions
- Tissue Plasminogen Activator (tPA), Isotonic solution
- Drug · Procedure
- Lead sponsor
- David Dornbos
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Acne Vulgaris, Post Inflammatory Hyperpigmentation
- Interventions
- ONEXTON Topical Gel
- Drug
- Lead sponsor
- Derm Research, PLLC
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky